Inovus Medical, a designer and manufacturer of medical and surgical simulation products, launched its Bozzini™ Hysteroscopy Simulator that has an anatomically correct uterus with interchangeable pathologies for practicing diagnosis and intraoperative management.

The pathologies include endometrial polyps, intrauterine adhesions and endometrial cancer/fibroid as well as a bicornate uterus. They offer life-like tissue handling and, the company says, are a low-cost way of delivering repeated practice of these core hysteroscopic skills. The uterus can be positioned in an anteverted and retroverted orientation allowing trainees to experience the correct approach needed for each.

The simulator comes with a standard 4mm hysteroscope, two hysteroscopic instruments, an HD camera system and a 15” monitor and monitor stand. The camera and hysteroscope are powered by the proprietary Bozzini™ light system that allows simulated endoscopic procedures to be performed with real endoscopic devices on a compact, table top simulator.

“The Bozzini™ Hysteroscopy Simulator offers a unique solution to the delivery of hysteroscopic simulation,” says Inovus Medical CTO and lead designer for the Bozzini™ project, Jordan Van Flute. He says, before the Bozzini™, options for training in hysteroscopy were limited to basic uterine models or full VR systems, both of which have drawbacks. “Basic uterine models require the acquisition and addition of expensive imaging systems, light sources and instruments, representing a significant overall cost to deliver training. The VR simulators represent a similar barrier to entry with high price points and often-expensive ongoing licensing fees and maintenance costs.”

The turnkey Bozzini™ solves these issues, the company says, by providing everything needed to deliver comprehensive hysteroscopic skills training in a single package. The launch of the Bozzini™ is supported by EIT Health through a 50,000 Euro Headstart award that helped Inovus expedite the final R&D stages and test bed activity. The company says having now tested the product with simulation centers across the UK, it will use the remainder of the Headstart funding in the launch and marketing of the new device.